Cargando…

HER2 as a potential biomarker of lymph node metastasis in undifferentiated early gastric cancer

Human epidermal growth factor receptor 2 (HER2) is implicated in several cancers, including gastric cancer. However, limited data are available regarding its clinical significance in early gastric cancer (EGC). We evaluated the clinical significance of HER2 overexpression in patients with EGC. We re...

Descripción completa

Detalles Bibliográficos
Autores principales: Han, Sanghoon, Park, Sungjin, An, Jungsuk, Yang, Jun-Young, Chung, Jun-Won, Kim, Yoon Jae, Kim, Kyoung Oh, Park, Dong Kyun, Kwon, Kwang An, Lee, Woon Kee, Nam, Seungyoon, Kim, Jung Ho
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7093413/
https://www.ncbi.nlm.nih.gov/pubmed/32210254
http://dx.doi.org/10.1038/s41598-020-61567-1
_version_ 1783510278560808960
author Han, Sanghoon
Park, Sungjin
An, Jungsuk
Yang, Jun-Young
Chung, Jun-Won
Kim, Yoon Jae
Kim, Kyoung Oh
Park, Dong Kyun
Kwon, Kwang An
Lee, Woon Kee
Nam, Seungyoon
Kim, Jung Ho
author_facet Han, Sanghoon
Park, Sungjin
An, Jungsuk
Yang, Jun-Young
Chung, Jun-Won
Kim, Yoon Jae
Kim, Kyoung Oh
Park, Dong Kyun
Kwon, Kwang An
Lee, Woon Kee
Nam, Seungyoon
Kim, Jung Ho
author_sort Han, Sanghoon
collection PubMed
description Human epidermal growth factor receptor 2 (HER2) is implicated in several cancers, including gastric cancer. However, limited data are available regarding its clinical significance in early gastric cancer (EGC). We evaluated the clinical significance of HER2 overexpression in patients with EGC. We retrospectively reviewed 727 patients who underwent surgical treatment for EGC between October 2010 and August 2017. HER2 expression was analysed in 680 EGC cases by immunohistochemistry and classified as negative (0 and 1+), equivocal (2+), or positive [overexpression (3+)]. Among patients with differentiated EGC, the number of patients with HER2 overexpression was not significantly different from that of HER2-negative patients in terms of age, sex, tumour size, location, gross type, depth of invasion, presence of lymphovascular invasion (LVI), and presence of lymph node metastasis (LNM). However, in patients with undifferentiated EGC, HER2 overexpression was significantly correlated with LVI and presence of LNM compared with HER2-negative patients. Multivariate analysis indicated HER2 overexpression as a good predictive marker of LNM in patients with undifferentiated EGC. HER2 expression is associated with LNM in undifferentiated EGC. Therefore, the importance of HER2 overexpression in EGC should not be overlooked, and further studies are needed to identify its clinical significance.
format Online
Article
Text
id pubmed-7093413
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-70934132020-03-27 HER2 as a potential biomarker of lymph node metastasis in undifferentiated early gastric cancer Han, Sanghoon Park, Sungjin An, Jungsuk Yang, Jun-Young Chung, Jun-Won Kim, Yoon Jae Kim, Kyoung Oh Park, Dong Kyun Kwon, Kwang An Lee, Woon Kee Nam, Seungyoon Kim, Jung Ho Sci Rep Article Human epidermal growth factor receptor 2 (HER2) is implicated in several cancers, including gastric cancer. However, limited data are available regarding its clinical significance in early gastric cancer (EGC). We evaluated the clinical significance of HER2 overexpression in patients with EGC. We retrospectively reviewed 727 patients who underwent surgical treatment for EGC between October 2010 and August 2017. HER2 expression was analysed in 680 EGC cases by immunohistochemistry and classified as negative (0 and 1+), equivocal (2+), or positive [overexpression (3+)]. Among patients with differentiated EGC, the number of patients with HER2 overexpression was not significantly different from that of HER2-negative patients in terms of age, sex, tumour size, location, gross type, depth of invasion, presence of lymphovascular invasion (LVI), and presence of lymph node metastasis (LNM). However, in patients with undifferentiated EGC, HER2 overexpression was significantly correlated with LVI and presence of LNM compared with HER2-negative patients. Multivariate analysis indicated HER2 overexpression as a good predictive marker of LNM in patients with undifferentiated EGC. HER2 expression is associated with LNM in undifferentiated EGC. Therefore, the importance of HER2 overexpression in EGC should not be overlooked, and further studies are needed to identify its clinical significance. Nature Publishing Group UK 2020-03-24 /pmc/articles/PMC7093413/ /pubmed/32210254 http://dx.doi.org/10.1038/s41598-020-61567-1 Text en © The Author(s) 2020 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
spellingShingle Article
Han, Sanghoon
Park, Sungjin
An, Jungsuk
Yang, Jun-Young
Chung, Jun-Won
Kim, Yoon Jae
Kim, Kyoung Oh
Park, Dong Kyun
Kwon, Kwang An
Lee, Woon Kee
Nam, Seungyoon
Kim, Jung Ho
HER2 as a potential biomarker of lymph node metastasis in undifferentiated early gastric cancer
title HER2 as a potential biomarker of lymph node metastasis in undifferentiated early gastric cancer
title_full HER2 as a potential biomarker of lymph node metastasis in undifferentiated early gastric cancer
title_fullStr HER2 as a potential biomarker of lymph node metastasis in undifferentiated early gastric cancer
title_full_unstemmed HER2 as a potential biomarker of lymph node metastasis in undifferentiated early gastric cancer
title_short HER2 as a potential biomarker of lymph node metastasis in undifferentiated early gastric cancer
title_sort her2 as a potential biomarker of lymph node metastasis in undifferentiated early gastric cancer
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7093413/
https://www.ncbi.nlm.nih.gov/pubmed/32210254
http://dx.doi.org/10.1038/s41598-020-61567-1
work_keys_str_mv AT hansanghoon her2asapotentialbiomarkeroflymphnodemetastasisinundifferentiatedearlygastriccancer
AT parksungjin her2asapotentialbiomarkeroflymphnodemetastasisinundifferentiatedearlygastriccancer
AT anjungsuk her2asapotentialbiomarkeroflymphnodemetastasisinundifferentiatedearlygastriccancer
AT yangjunyoung her2asapotentialbiomarkeroflymphnodemetastasisinundifferentiatedearlygastriccancer
AT chungjunwon her2asapotentialbiomarkeroflymphnodemetastasisinundifferentiatedearlygastriccancer
AT kimyoonjae her2asapotentialbiomarkeroflymphnodemetastasisinundifferentiatedearlygastriccancer
AT kimkyoungoh her2asapotentialbiomarkeroflymphnodemetastasisinundifferentiatedearlygastriccancer
AT parkdongkyun her2asapotentialbiomarkeroflymphnodemetastasisinundifferentiatedearlygastriccancer
AT kwonkwangan her2asapotentialbiomarkeroflymphnodemetastasisinundifferentiatedearlygastriccancer
AT leewoonkee her2asapotentialbiomarkeroflymphnodemetastasisinundifferentiatedearlygastriccancer
AT namseungyoon her2asapotentialbiomarkeroflymphnodemetastasisinundifferentiatedearlygastriccancer
AT kimjungho her2asapotentialbiomarkeroflymphnodemetastasisinundifferentiatedearlygastriccancer